ArticleMolecular psychiatry2021
Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Understanding Remission of Long-Term Conditions Through Electronic Health Records: Scoping Review.Journal of medical Internet research · 2026Article
- From In Silico Hypothesis to Validation: The Role of Real-World Evidence in the Preliminary Verification of AI-Generated Drug-Repositioning Candidates: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Olanzapine Attenuates the Morphine-Induced Conditioned Place Preference: The Involvement of the D2-Like Dopamine Receptors.Brain and behavior · 2026Article
- Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases.Translational psychiatry · 2025Article
- Artificial intelligence approaches for anti-addiction drug discovery.Digital discovery · 2025Review
- Leveraging pleiotropy for the improved treatment of psychiatric disorders.Molecular psychiatry · 2025Review
- Research agenda evaluating measurement-based care for opioid use disorder among patients with co-occurring depressive disorders.Frontiers in psychiatry · 2025Article
- Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacological reviews · 2023Review
- Potential effect of antidepressants on remission from cocaine use disorder - A nationwide matched retrospective cohort study.Drug and alcohol dependence · 2023Article
- Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.Addiction (Abingdon, England) · 2023Article
- The Role of Physical Exercise in Opioid Substitution Therapy: Mechanisms of Sequential Effects.International journal of molecular sciences · 2023Review
- Re-Purposing FDA-Approved Drugs for Opioid Use Disorder.Substance use & misuse · 2023Observational
- Effectiveness of Artificial Intelligence Methods in Personalized Aggression Risk Prediction within Inpatient Psychiatric Treatment Settings-A Systematic Review.Journal of personalized medicine · 2022Review
- Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders.Pharmaceutics · 2022Review
- Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records.BMC medical informatics and decision making · 2022Article
- Computational drug repurposing based on electronic health records: a scoping review.NPJ digital medicine · 2022Article
- Artificial intelligence and Psychiatry: An overview.Asian journal of psychiatry · 2022Review
- A knowledge graph-based disease-gene prediction system using multi-relational graph convolution networks.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022Article
- The use of real-world data in drug repurposing.Translational and clinical pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Morbidity and mortality from opioid use disorders (OUD) and other substance use disorders (SUD) is a major public health crisis, yet there are few medications to treat them. There is an urgency to accelerate SUD medication development. We present an integrated drug repurposing strategy that combines computational prediction, clinical corroboration using electronic health records (EHRs) of over 72.9 million patients and mechanisms of action analysis. Among top-ranked repurposed candidate drugs, tramadol, olanzapine, mirtazapine, bupropion, and atomoxetine were associated with increased odds of OUD remission (adjusted odds ratio: 1.51 [1.38-1.66], 1.90 [1.66-2.18], 1.38 [1.31-1.46], 1.37 [1.29-1.46], 1.48 [1.25-1.76], p value < 0.001, respectively). Genetic and functional analyses showed these five candidate drugs directly target multiple OUD-associated genes including BDNF, CYP2D6, OPRD1, OPRK1, OPRM1, HTR1B, POMC, SLC6A4 and OUD-associated pathways, including opioid signaling, G-protein activation, serotonin receptors, and GPCR signaling. In summary, we developed an integrated drug repurposing approach and identified five repurposed candidate drugs that might be of value for treating OUD patients, including those suffering from comorbid conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.